BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 35805976)

  • 1. Immunohistochemical Profile of Parathyroid Tumours: A Comprehensive Review.
    Uljanovs R; Sinkarevs S; Strumfs B; Vidusa L; Merkurjeva K; Strumfa I
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into Hyperparathyroidism-Jaw Tumour Syndrome: From Endocrine Acumen to the Spectrum of
    Gheorghe AM; Sima OC; Florescu AF; Ciuche A; Nistor C; Sandru F; Carsote M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas.
    Juhlin CC; Nilsson IL; Johansson K; Haglund F; Villablanca A; Höög A; Larsson C
    Endocr Pathol; 2010 Sep; 21(3):166-77. PubMed ID: 20473645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of the 2022 WHO Classification of Parathyroid Tumors.
    Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
    Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic significance of parafibromin expression in parathyroid carcinoma.
    Gao Y; Wang P; Lu J; Pan B; Guo D; Zhang Z; Wang A; Zhang M; Sun J; Wang W; Liang Z
    Hum Pathol; 2022 Sep; 127():28-38. PubMed ID: 35654240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
    Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
    Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice deleted for cell division cycle 73 gene develop parathyroid and uterine tumours: model for the hyperparathyroidism-jaw tumour syndrome.
    Walls GV; Stevenson M; Lines KE; Newey PJ; Reed AAC; Bowl MR; Jeyabalan J; Harding B; Bradley KJ; Manek S; Chen J; Wang P; Williams BO; Teh BT; Thakker RV
    Oncogene; 2017 Jul; 36(28):4025-4036. PubMed ID: 28288139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma.
    Kim HK; Oh YL; Kim SH; Lee DY; Kang HC; Lee JI; Jang HW; Hur KY; Kim JH; Min YK; Chung JH; Kim SW
    Head Neck; 2012 Feb; 34(2):201-6. PubMed ID: 21717519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Characteristics of Large Parathyroid Adenomas.
    Agarwal A; Pradhan R; Kumari N; Krishnani N; Shukla P; Gupta SK; Chand G; Mishra A; Agarwal G; Verma AK; Mishra SK
    World J Surg; 2016 Mar; 40(3):607-14. PubMed ID: 26669787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
    Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
    Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filamin A and parafibromin expression in parathyroid carcinoma.
    Storvall S; Leijon H; Ryhänen EM; Vesterinen T; Heiskanen I; Schalin-Jäntti C; Arola J
    Eur J Endocrinol; 2021 Oct; 185(6):803-812. PubMed ID: 34606470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of parafibromin expression in a subset of parathyroid adenomas.
    Juhlin C; Larsson C; Yakoleva T; Leibiger I; Leibiger B; Alimov A; Weber G; Höög A; Villablanca A
    Endocr Relat Cancer; 2006 Jun; 13(2):509-23. PubMed ID: 16728578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma.
    Howell VM; Gill A; Clarkson A; Nelson AE; Dunne R; Delbridge LW; Robinson BG; Teh BT; Gimm O; Marsh DJ
    J Clin Endocrinol Metab; 2009 Feb; 94(2):434-41. PubMed ID: 19017757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parafibromin, APC, and MIB-1 Are Useful Markers for Distinguishing Parathyroid Carcinomas From Adenomas.
    Hosny Mohammed K; Siddiqui MT; Willis BC; Zaharieva Tsvetkova D; Mohamed A; Patel S; Sharma J; Weber C; Cohen C
    Appl Immunohistochem Mol Morphol; 2017; 25(10):731-735. PubMed ID: 27490759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas.
    Wang O; Wang C; Nie M; Cui Q; Guan H; Jiang Y; Li M; Xia W; Meng X; Xing X
    PLoS One; 2012; 7(9):e45567. PubMed ID: 23029104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma.
    Witteveen JE; Hamdy NA; Dekkers OM; Kievit J; van Wezel T; Teh BT; Romijn JA; Morreau H
    Mod Pathol; 2011 May; 24(5):688-97. PubMed ID: 21240254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic performance of parafibromin immunohistochemical staining for sporadic parathyroid carcinoma: a meta-analysis.
    Hu Y; Liao Q; Cao S; Gao X; Zhao Y
    Endocrine; 2016 Dec; 54(3):612-619. PubMed ID: 27250989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.